MP27-04 MULTI-CENTER REPORT ON ACUTE CLINICAL OUTCOMES WITH RIVERMARK FloSTENT™

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology II (MP27)1 May 2024MP27-04 MULTI-CENTER REPORT ON ACUTE CLINICAL OUTCOMES WITH RIVERMARK FloSTENT™ Peter Gilling, Peter Chin, Javier Sanchez, Ingrid Perscky, Ruben Urena, and Dean Elterman Peter GillingPeter Gilling , Peter ChinPeter Chin , Javier SanchezJavier Sanchez , Ingrid PersckyIngrid Perscky , Ruben UrenaRuben Urena , and Dean EltermanDean Elterman View All Author Informationhttps://doi.org/10.1097/01.JU.0001009400.86696.a2.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The Rivermark FloStent™ is a novel BPH device that can be delivered via the working channel of any flexible cystoscope, in an outpatient setting with no need for a post-procedure catheter. The purpose of this analysis was to characterize the perioperative experience and rapidity of treatment response in a multi-center setting. METHODS: Acute (two-week) clinical outcomes from two ethics-approved clinical trials were pooled and analyzed. Analyzed patients had prostatic size 20-80 mL, prostatic urethral length 2-5 cm, baseline IPSS>13, and baseline QMax<13 mL/s. RESULTS: 34 male subjects (mean age 61.2±10.7 yr) implanted with FloStent at four centers in Panama, Australia, New Zealand, and Mexico were included in the analysis. Mean prostatic volume was 46.4±15.8 mL (range 20-78). Implantations were performed by seven different surgeons, each time using a flexible cystoscope, in an outpatient setting. All attempted implantations were successful. No patient required a post-procedure catheter. Four different types of scopes were used (Storz, Olympus, SeeSheen, Ambu). Devices were implanted using either standard grasping forceps (n=7) or a proprietary delivery tool (n=27). All patients voided spontaneously prior to same-day discharge. No device-related SAEs or UAEs were recorded. Across the cohort, mean IPSS score dropped from 23.8±4.5 to 12.3±9.0 at the two-week timepoint, while mean QOL score dropped from 5.1±0.8 to 2.3±1.7 (Figure 1). Early symptom reduction with Rivermark FloStent™. CONCLUSIONS: The Rivermark FloStent™ is a catheter-free BPH device therapy that rapidly reduces bother from LUTS. There appears to be a short learning curve, excellent safety profile, and early enhancement in quality-of-life. Download PPT Source of Funding: Rivermark Medical, Inc © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e424 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Peter Gilling More articles by this author Peter Chin More articles by this author Javier Sanchez More articles by this author Ingrid Perscky More articles by this author Ruben Urena More articles by this author Dean Elterman More articles by this author Expand All Advertisement PDF downloadLoading ...